Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy

IntroductionIn oncology, anti-drug antibody (ADA) development that significantly curtails response durability has not historically risen to a level of concern. The relevance and attention ascribed to ADAs in oncology clinical studies have therefore been limited, and the extant literature on this sub...

詳細記述

書誌詳細

出版年:	Frontiers in Immunology
主要な著者:	Hweixian Leong Penny, Kelly Hainline, Nathaniel Theoharis, Bin Wu, Christian Brandl, Christian Webhofer, Mason McComb, Sabine Wittemer-Rump, Gökben Koca, Sabine Stienen, Ralf C. Bargou, Horst-Dieter Hummel, Wolfgang Loidl, Carsten Grüllich, Tobias Eggert, Ben Tran, Daniel T. Mytych
フォーマット:	論文
言語:	英語
出版事項:	Frontiers Media S.A. 2023-10-01
主題:	immunogenicity BiTE® T cell engager ADA prostate cancer
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1261070/full